公开(公告)号：US11655289B2

公开(公告)日：2023-05-23

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: A61K39/395 ,  C07K16/18 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/94

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.

公开(公告)号：US20210188954A1

公开(公告)日：2021-06-24

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/18 ,  A61K47/26 ,  A61K47/22 ,  A61K47/20

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.

公开(公告)号：US20190064147A1

公开(公告)日：2019-02-28

申请号：US15544315

申请日：2016-01-18

Applicant: Biogen MA Inc.

Inventor： Mark Krebs ,  Mariana Dimitrova ,  Kapil Gupta ,  Shantanu Sule ,  Randall Mauldin ,  Adnan Zunic ,  Lori Karpes

IPC: G01N33/50 ,  A61K47/12 ,  G01N33/68 ,  A61K47/18 ,  A61K47/26 ,  G01N33/84 ,  G01N33/94 ,  C07K1/113 ,  G01N33/15

Abstract: Provided herein, in some aspects, are methods of developing a biological therapeutic product. The methods can be used to formulate a biological therapeutic agent or screen biological therapeutic agents.

公开(公告)号：US20180264112A1

公开(公告)日：2018-09-20

申请号：US15543653

申请日：2016-01-15

Applicant: Biogen MA Inc.

Inventor： Mark Krebs ,  Adnan Zunic ,  Tia Estey ,  Shantanu Sule ,  Margaret McGrath ,  Lori Karpes ,  Yana Kravets

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K9/00 ,  A61K47/22

CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/54 ,  C07K16/2878 ,  C07K2317/56 ,  C07K2317/565

Abstract: Provided herein, in some aspects, are low viscosity, low aggregation propensity, high anti-CD40 antibody concentration formulations.

公开(公告)号：US20240043513A1

公开(公告)日：2024-02-08

申请号：US18300339

申请日：2023-04-13

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or Aβ-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and Aβ-associated disorders such as Alzheimer's disease.

公开(公告)号：US20190284281A1

公开(公告)日：2019-09-19

申请号：US16095475

申请日：2017-04-27

Applicant: Biogen MA Inc.

Inventor： Mark R.H. Krebs ,  David Dai ,  Shantanu Sule ,  Dania Rabah ,  David Martin

IPC: C07K16/28 ,  A61K9/00 ,  A61P37/06

Abstract: Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.